Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM et al..  2017.  Differential Growth Rates of Benign vs. Malignant Thyroid Nodules.. J Clin Endocrinol Metab. 102(12):4642-4647.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.  2017.  Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.. J Clin Oncol. 35(23):2692-2699.

Zhang Y, Yu J, Grachtchouk V, Qin T, Lumeng CN, Sartor MA, Koenig RJ.  2017.  Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.. Oncotarget. 8(4):5761-5773.

Glomski K, Nosé V, Faquin WC, Sadow PM.  2017.  Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination: Institutional Review of Cases from 1990 to 2015.. Endocr Pathol. 28(2):177-185.

Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EEW, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.  2016.  Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.. Cancer. 122(24):3856-3864.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.  2014.  p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.. Proc Natl Acad Sci U S A. 111(16):E1600-9.